Current strategies for immunosuppression following liver transplantation

Langenbeck's Archives of Surgery

Volumn 399, Issue 8, 2014, Pages 981-988

  Gotthardt, Daniel Nils ^a   Bruns, Helge ^a   Weiss, Karl Heinz ^a   Schemmer, Peter ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Calcineurin minimization; IL 2; Induction; Operational tolerance; Steroid reduction; Tacrolimus trough levels

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; DACLIZUMAB; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; PROTEINURIA; REVIEW; GRAFT REJECTION; PROCEDURES;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 84911991463     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-014-1191-9     Document Type: Review

References (67)

1. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, Blanchard H et al (1968) Orthotopic homotransplantation of the human liver. Ann Surg 168:392–415
2. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P et al (2003) Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 9:1231–1243. doi:10.1016/j.lts.2003.09.018
3. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, Abu-Elmagd K et al (2000) Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 232:490–500
4. Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, Guckelberger O et al (2013) Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant 13:2384–2394. doi:10.1111/ajt.12384
5. Dienstag JL, Cosimi AB (2012) Liver transplantation—a vision realized. N Engl J Med 367:1483–1485. doi:10.1056/NEJMp1210159
6. Alex Bishop G, Bertolino PD, Bowen DG, McCaughan GW (2012) Tolerance in liver transplantation. Best Pract Res Clin Gastroenterol 26:73–84. doi:10.1016/j.bpg.2012.01.003
7. Sanchez-Fueyo A (2011) Hot-topic debate on tolerance: immunosuppression withdrawal. Liver Transpl 17(Suppl 3):S69–73. doi:10.1002/lt.22421
8. Scherer MN, Banas B, Mantouvalou K, Schnitzbauer A, Obed A, Kramer BK, Schlitt HJ (2007) Current concepts and perspectives of immunosuppression in organ transplantation. Langenbeck's Arch Surg/Deutsche Gesellschaft fur Chirurgie 392:511–523. doi:10.1007/s00423-007-0188-z
9. Londono MC, Rimola A, O'Grady J, Sanchez-Fueyo A (2013) Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol 59:872–879. doi:10.1016/j.jhep.2013.04.003
10. Wiesner RH, Fung JJ (2011) Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 17(Suppl 3):S1–9. doi:10.1002/lt.22410
11. Schlitt HJ, Loss M, Scherer MN, Becker T, Jauch KW, Nashan B, Schmidt H et al (2011) Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres. Z Gastroenterol 49:30–38. doi:10.1055/s-0029-1245946
12. Weismuller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, Paul A et al (2011) Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany—limitations of the 'sickest first'-concept. Transpl Int 24:91–99. doi:10.1111/j.1432-2277.2010.01161.x
13. Geissler EK, Schlitt HJ (2009) Immunosuppression for liver transplantation. Gut 58:452–463. doi:10.1136/gut.2008.163527
14. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) (2012) OPTN/SRTR 2011 Annual Data Report in Excel. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. http://srtr.transplant.hrsa.gov/annual_reports/2011/. Accessed 5 January 2014
15. Rodriguez-Peralvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, Rolando N et al (2013) Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol 58:262–270. doi:10.1016/j.jhep.2012.09.019
16. Turner AP, Knechtle SJ (2013) Induction immunosuppression in liver transplantation: a review. Transpl Int 26:673–683. doi:10.1111/tri.12100
17. Cai J, Terasaki PI (2010) Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplant 90:1511–1515. doi:10.1097/TP.0b013e3181fecfcb
18. Mangus RS, Fridell JA, Vianna RM, Kwo PY, Chen J, Tector AJ (2012) Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 18:786–795. doi:10.1002/lt.23381
19. Beckebaum S, Cicinnati VR, Radtke A, Kabar I (2013) Calcineurin inhibitors in liver transplantation—still champions or threatened by serious competitors? Liver Int 33:656–665. doi:10.1111/liv.12133
20. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E et al (2002) Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 8:132–142. doi:10.1053/jlts.2002.30302
21. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH et al (2002) Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 8:123–131. doi:10.1053/jlts.2002.30882
22. Xing T, Huang L, Yu Z, Zhong L, Wang S, Peng Z (2013) Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma. PLoS One 8:e71251. doi:10.1371/journal.pone.0071251
23. Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, Guarrera JV et al (2011) Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplant 91:1254–1260. doi:10.1097/TP.0b013e318218f0f5
24. Levitsky J, Thudi K, Ison MG, Wang E, Abecassis M (2011) Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl 17:32–37. doi:10.1002/lt.22180
25. Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK (2012) Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant 12:2797–2814. doi:10.1111/j.1600-6143.2012.04140.x
26. Ramirez CB, Doria C, Frank AM, Armenti ST, Marino IR (2013) Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant 27:463–471. doi:10.1111/ctr.12119
27. De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S et al (2012) Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 12:3008–3020. doi:10.1111/j.1600-6143.2012.04212.x
28. Rodriguez-Peralvarez M, Manousou P, Lerut J, De la Mata M, Burroughs AK (2013) How much immunosuppression is needed after liver transplantation? Clin Transplant. doi:10.1111/ctr.12242
29. Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, De la Mata M, Burroughs AK (2013) Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. Am J Transplant 13:1371–1372. doi:10.1111/ajt.12216
30. Penninga L, Wettergren A, Chan AW, Steinbruchel DA, Gluud C (2012) Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database Syst Rev 3, CD008852. doi:10.1002/14651858.CD008852.pub2
31. Barbier L, Garcia S, Cros J, Borentain P, Botta-Fridlund D, Paradis V, Le Treut YP et al (2013) Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors. J Hepatol 59:1223–1230. doi:10.1016/j.jhep.2013.07.032
32. Creput C, Blandin F, Deroure B, Roche B, Saliba F, Charpentier B, Samuel D et al (2007) Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 13:1004–1010. doi:10.1002/lt.21170
33. Orlando G, Baiocchi L, Cardillo A, Iaria G, De LiguoriCarino N, De Luca L, Ielpo B et al (2007) Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 13:46–54. doi:10.1002/lt.20926
34. Boudjema K, Camus C, Saliba F, Calmus Y, Salame E, Pageaux G, Ducerf C et al (2011) Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 11:965–976. doi:10.1111/j.1600-6143.2011.03486.x
35. Manousou P, Cholongitas E, Samonakis D, Tsochatzis E, Corbani A, Dhillon AP, Davidson J et al (2013) Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut. doi:10.1136/gutjnl-2013-305606
36. De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, Ducci J et al (2009) Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 22:279–286. doi:10.1111/j.1432-2277.2008.00768.x
37. Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, Settmacher U et al (2012) A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation—PROTECT. Am J Transplant 12:1855–1865. doi:10.1111/j.1600-6143.2012.04049.x
38. Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, Begliomini B et al (2010) Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 10:2252–2262. doi:10.1111/j.1600-6143.2010.03128.x
39. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L et al (2009) Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 15:1262–1269. doi:10.1002/lt.21827
40. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Jonas S et al (2013) Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 13:1734–1745. doi:10.1111/ajt.12280
41. Vallin M, Guillaud O, Morard I, Gagnieu MC, Mentha G, Adham M, Morelon E et al (2011) Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant 25:660–669. doi:10.1111/j.1399-0012.2010.01370.x
42. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, Schemmer P et al (2014) Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. doi:10.1111/ajt.12615
43. Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, Winkler S et al (2013) Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma—systematic review and meta-analysis. Cancer Med 2:862–871. doi:10.1002/cam4.150
44. Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, Neff GW et al (2012) Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 12:694–705. doi:10.1111/j.1600-6143.2011.03919.x
45. Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, Koneru B et al (2013) Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 19:675–689. doi:10.1002/lt.23658
46. Dumortier J, Guillaud O, Boillot O (2013) Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. Liver Transpl 19:529–533. doi:10.1002/lt.23638
47. Heffron TG, Pescovitz MD, Florman S, Kalayoglu M, Emre S, Smallwood G, Wisemandle K et al (2007) Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 7:1609–1615. doi:10.1111/j.1600-6143.2007.01803.x
48. Trunecka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, Troisi RI et al (2010) Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 10:2313–2323. doi:10.1111/j.1600-6143.2010.03255.x
49. Sgourakis G, Radtke A, Fouzas I, Mylona S, Goumas K, Gockel I, Lang H et al (2009) Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 22:892–905. doi:10.1111/j.1432-2277.2009.00893.x
50. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA et al (2008) Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 14:512–525. doi:10.1002/lt.21396
51. Moench C, Barreiros AP, Schuchmann M, Bittinger F, Thiesen J, Hommel G, Kraemer I et al (2007) Tacrolimus monotherapy without steroids after liver transplantation—a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 7:1616–1623. doi:10.1111/j.1600-6143.2007.01804.x
52. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G (2010) Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 90:1562–1566. doi:10.1097/TP.0b013e3181ff8794
53. Lerut J, Mathys J, Verbaandert C, Talpe S, Ciccarelli O, Lemaire J, Bonaccorsi-Riani E et al (2008) Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg 248:956–967. doi:10.1097/SLA.0b013e31819009c9
54. Manzia TM, Toti L, Angelico R, Di Cocco P, Orlando G, Tisone G (2010) Steroid-free immunosuppression after liver transplantation does not increase the risk of graft fibrosis. Transplant Proc 42:1237–1239. doi:10.1016/j.transproceed.2010.03.118
55. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA et al (2011) A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 17:1394–1403. doi:10.1002/lt.22417
56. Zaydfudim V, Feurer ID, Landman MP, Moore DE, Wright JK, Pinson CW (2012) Reduction in corticosteroids is associated with better health-related quality of life after liver transplantation. J Am Coll Surg 214:164–173. doi:10.1016/j.jamcollsurg.2011.10.006
57. Saliba F, Dharancy S, Lorho R, Conti F, Radenne S, Neau-Cransac M, Hurtova M et al (2011) Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl 17:905–913. doi:10.1002/lt.22292
58. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR (2005) Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 11:750–759. doi:10.1002/lt.20453
59. Schmeding M, Kiessling A, Neuhaus R, Heidenhain C, Bahra M, Neuhaus P, Neumann UP (2011) Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplant 92:923–929. doi:10.1097/TP.0b013e31822d880d
60. Chandrasekharan D, Issa F, Wood KJ (2013) Achieving operational tolerance in transplantation: how can lessons from the clinic inform research directions? Transpl Int 26:576–589. doi:10.1111/tri.12081
61. Porrett P, Shaked A (2011) The failure of immunosuppression withdrawal: patient benefit is not detectable, inducible, or reproducible. Liver Transpl 17(Suppl 3):S66–68. doi:10.1002/lt.22377
62. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, Alonso EM et al (2012) Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. Jama 307:283–293. doi:10.1001/jama.2011.2014
63. Benitez C, Londono MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, Martinez-Llordella M et al (2013) Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. doi:10.1002/hep.26426
64. Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A, Lerut J et al (2007) Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 7:309–319. doi:10.1111/j.1600-6143.2006.01621.x
65. de la Garza RG, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA et al (2013) Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl 19:937–944. doi:10.1002/lt.23686
66. Paterno F, Shiller M, Tillery G, O'Leary JG, Susskind B, Trotter J, Klintmalm GB (2012) Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 12:2526–2531. doi:10.1111/j.1600-6143.2012.04126.x
67. Abu-Elmagd KM, Wu G, Costa G, Lunz J, Martin L, Koritsky DA, Murase N et al (2012) Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant 12:3047–3060. doi:10.1111/j.1600-6143.2012.04237.x